WESTMINSTER, CA / ACCESSWIRE / October 14, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary BioLargo Energy Technologies, Inc. completed preliminary internal testing of its prototype battery cells confirming many of the technology's exceptional performance claims that make it an attractive battery technology for long duration energy storage.

The tests, done to verify the battery's performance claims made by its original inventors, confirmed the stability of the chemistry of the battery cell and the reliability of the component construction as a sealed, non-venting cell design with no self-discharging. The tests also helped verify the battery's ability to quickly charge and discharge at a high voltage.

Cellinity? is BioLargo's next-generation battery platform designed to provide a better alternative to lithium-ion technology for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is safer, more sustainable, longer lasting, and more energy-dense than lithium-ion batteries, traits that make it ideal for large-format long-duration energy storage applications. Learn more about Cellinity at www.BioLargoEnergy.com.

In addition to these internal tests, the company is also organizing third-party validation testing to be done on the more complex aspects of Cellinity's electrochemical performance with at least two acclaimed testing facilities.

Dennis P. Calvert, President and CEO of BioLargo, commented "With these results in hand, our engineers are now advancing the next steps in Cellinity's development: design and production of the larger format 'Spartan' Cellinity cells, and design and production of battery modules containing those cells. Stay tuned - we're very excited about the future of this important battery technology, and we think you should be too."

He continued, "According to a recently published article in The Economist titled 'Clean energy's next trillion-dollar business', global energy storage experts have predicted the global supply of battery energy storage will need to increase from today's 200 gigawatts to more than a terawatt by 2030 and more than five terawatts by 2050, fueling a market projected to be worth between $200 billion and $700 billion by 2030 and between $1 and $3 trillion by 2040. These projections underscore the critical role of batteries in the global energy transition and the massive global investment in battery innovation required to meet those targets. Because of its unique differentiators in safety, energy density, and lifespan, Cellinity is especially well-suited to assist in the global energy transition, and we intend to capitalize on that."

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Contact Information

Dennis Calvert
President and CEO
[email protected]
(888) 400-2863

SOURCE: BioLargo, Inc.

View the original press release on accesswire.com